BioLineRx Establishes Oncology Scientific Advisory Board
The members of BioLineRx’s SAB include four renowned clinicians and
translational scientists in oncology. These include: Professor
BioLineRx’s Scientific Advisory Board Members:
Professor
Dr. Cortes is Professor of
Medicine and Deputy Chair, and is also the Chief of the CML and AML
Sections of the
Dr. Roychowdhury is a leader in
the pharmaceutical industry with a strong background in oncology
research and development, and regulatory and commercial operations,
having previously served in key senior leadership roles at
Prof.
Prof.
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.
In December 2014, BioLineRx entered into a strategic collaboration
with Novartis for the co-development of selected Israeli-sourced novel
drug candidates. The companies intend to co-develop a number of
pre-clinical and early clinical therapeutic projects through clinical
proof-of-concept for potential future licensing by
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the “Risk Factors” section
of BioLineRx’s most recent annual report on Form 20-F filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20151203005502/en/
Source:
PCG Advisory
Vivian Cervantes, 212-554-5482
Investor Relations
vivian@pcgadvisory.com
or
for
BioLineRx Ltd.
Tsipi Haitovsky, +972-3-624-0871
Public
Relations
tsipihai5@gmail.com